查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1863147

全球疼痛管理设备市场：洞察、竞争格局及至2032年预测

Pain Management Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

疼痛管理设备市场摘要

  • 全球疼痛管理设备市场预计将从 2024 年的 52.773 亿美元成长到 2032 年的 93.5072 亿美元，反映出强劲且持续的成长。
  • 全球疼痛管理设备市场在 2025 年至 2032 年的预测期内将以 7.53% 的复合年增长率成长。
  • 受慢性疼痛盛行率上升、新产品频繁上市以及人们对疼痛管理解决方案的认知不断提高的推动，全球疼痛管理设备市场预计将在2025年至2032年间快速成长。对微创设备的需求不断增长以及相关的宣传宣传活动正在推动这些设备的普及，为创新和改善患者疗效创造了强劲的机会。
  • 在疼痛管理设备市场中运作的主要企业包括：雅培实验室、史密斯医疗、贝朗公司、百特国际、波士顿科学公司、Avanos Medical公司、美敦力、Nevro公司、ICU Medical公司、欧姆龙公司、Stimwave LLC、Nipro、O&M Halyard、EndoStim公司、Nalu Medicalyn、Micrelwave、Micrel Medicali​​Y、Danoi​​Y
  • 由于慢性疼痛负担沉重、意识提升提升、政府支持计划以及不断的产品创新和频繁的 FDA核准，预计北美将继续保持其在疼痛管理设备市场的主导地位。
  • 根据设备类型划分，预计到 2024 年，疼痛管理设备市场将占据最大的市场份额，其中神经刺激设备类别将占据 100% 的市场份额。

疼痛管理设备市场成长要素

  • 慢性疼痛及相关疾病的日益普遍导致疼痛管理设备市场迅速扩张：这不是一个单一的孤立因素，而是由多个相互关联的人口和健康趋势造成的复杂问题。
  • 人口老化：随着全球预期寿命的延长，65岁及以上人口的比例不断增加。这种人口结构变化与慢性疼痛盛行率的上升直接相关。老年人更容易患上与老龄化相关的疾病，这些疾病会导致持续性疼痛，例如：
  • 骨关节炎：骨关节炎：一种随着老龄化而日益常见的退化性关节疾病。
  • 肌肉骨骼疾病：包括背痛，这是全球造成残疾的主要原因之一。
  • 神经病变疼痛：老龄化相关的神经损伤引起的神经相关疼痛。
  • 慢性疾病：糖尿病和癌症等慢性疾病在全球造成的负担日益加重，导致神经病变疼痛和其他需要长期治疗的疼痛形式日益普遍。
  • 糖尿病：糖尿病会导致一种称为糖尿病性神经病变的神经病变，进而引起慢性疼痛、麻木和瘫痪。
  • 癌症：疾病本身及其治疗（化疗、放射线治疗等）都会引起剧烈且持续的疼痛。
  • 肥胖：会对关节和骨骼系统造成压力，增加背部、膝盖和髋部疼痛的发生率。
  • 生活方式的改变：久坐的生活方式和职业因素导致腰痛和其他肌肉骨骼问题等疾病的增加，从而刺激了对非药物止痛的需求。
  • 久坐的生活方式：长时间坐在文书工作或萤幕前会导致姿势不良和慢性背部和颈部疼痛。
  • 重复性劳损会导致腕隧道症候群和其他肌腱炎等疾病。
  • 摆脱鸦片类药物镇痛：这是推动镇痛设备市场成长的关键因素，也是对全球公共卫生危机的直接回应。
  • 鸦片类药物危机及其影响：全球鸦片类药物危机凸显了传统止痛药成瘾、误用和滥用的风险。这促使医疗专业人员、患者和监管机构积极寻求更安全、无成瘾性的替代方案。此外，阿片类镇痛药在治疗急性和慢性疼痛方面的过度处方已导致许多国家，特别是美国，出现公共卫生危机。主要问题包括：
  • 成瘾与滥用：许多因疼痛管理而服用鸦片类药物的人会发展出成瘾和依赖性，这可能导致物质使用障碍，在某些情况下，还会导致更危险的非法鸦片类药物，如海洛因或Fentanyl。
  • 过量用药致死：处方药和非法鸦片类药物导致的过量用药致死现象十分普遍，是意外伤害致死的主要原因。
  • 公众和专家的关注：这场危机的规模引起了公众、卫生专业人员和政策制定者的广泛关注，从而强烈推动非药物替代疗法。
  • 减少副作用：疼痛管理设备，尤其是非侵入性设备，提供了一种缓解疼痛的方法，而不会像口服止痛药那样产生全身性副作用（如嗜睡、噁心和便秘）。
  • 多模态疼痛管理的兴起：减少鸦片类药物的使用正在加速多模态疼痛管理方法的普及，这种方法结合多种不同的治疗方法以达到最佳的疼痛缓解效果。疼痛管理设备完美契合这种模式，因为它们可以与非鸦片类药物（例如非类固醇抗发炎药）、物理治疗和其他干预措施联合使用。例如，术后復健患者可以使用经皮神经电刺激（TENS）设备来控制术后疼痛，从而减少对口服鸦片类药物的需求。

摘要，鸦片类药物危机犹如一记强劲的催化剂，迫使人们从根本上改变疼痛治疗方式。这为疼痛管理设备创造了巨大的市场机会，这些设备被定位为比传统药物镇痛更安全、无成瘾性且更有效的替代方案。

  • 技术进步与创新
  • 神经调控技术：神经刺激技术的突破性进展，包括闭合迴路系统和微型植入式设备，使这些治疗方法更有效、更个人化、侵入性更小。
  • 智慧型穿戴装置：可携式、使用者友善的穿戴装置（例如 TENS 装置）的开发，使得在家中进行疼痛管理更加方便，减少了频繁就医的需要。
  • 与数位健康融合：人工智慧 (AI)、远端监测和数位健康平台的融合将实现更精准、数据主导的疼痛管理，从而改善患者的治疗效果。

疼痛管理设备市场报告细分

本疼痛管理设备市场报告全面概​​述了全球疼痛管理设备市场，重点分析了关键趋势、成长驱动因素、挑战和机会。报告按设备类型、应用、最终用户和地区对市场进行细分，深入剖析了北美、欧洲和亚太等主要市场的竞争格局、监管环境和市场动态。报告详细介绍了行业领导者的概况和最新产品开发情况，为企业提供关键数据，帮助其识别市场潜力、制定策略规划，并在快速成长的疼痛管理设备市场中掌握新机会。

疼痛管理设备是一类旨在缓解疼痛的医疗设备，其作用机制无需口服药物（尤其是鸦片类药物）或可作为口服药物的替代方案。这些医疗设备透过刺激人体自身的疼痛缓解机製或阻断疼痛讯号传递至大脑来发挥作用。它们可用于治疗多种慢性及急性疼痛，包括肌肉骨骼疾病、神经病变疼痛以及术后恢復期疼痛。

慢性疼痛盛行率的不断上升，以及产品上市数量的增加和人们对疼痛管理解决方案认知度的提高，预计将推动全球疼痛管理设备市场显着成长。患者对有效、微创治疗的需求日益增长，加剧了市场竞争和技术创新，主要企业正不断推出先进设备以拓展治疗选择。此外，宣传宣传活动和患者权益倡导也促进了这些技术在全球的普及和应用。预计在2025年至2032年的预测期内，这些因素将改善慢性疼痛患者的治疗效果，并提高其生活质量，从而为市场扩张创造有利环境。

全球疼痛管理设备市场正经历强劲成长，这主要得益于肿瘤、肌肉骨骼和神经系统疾病等慢性疼痛疾病盛行率的不断上升。尤其是神经性神经病变（NCP），传统治疗方法往往难以有效控制。全球癌症患者数量的快速增长，包括乳癌、肺癌和前列腺癌患者，持续推动对先进疼痛管理解决方案的需求。根据DelveInsight（2024）的数据显示，2023年七大主要国家的三阴性乳癌（TNBC）病例数约为10.2万例。 2022年全球乳癌发生率达230万例，预计2045年将成长至336万例。不断扩大的患者群体凸显了创新设备在有效缓解疼痛和改善患者生活品质方面的重要作用。

根据《全球疾病负担报告》（2023年版），预计到2050年，骨关节炎将影响近10亿人，其中膝关节（增长74.9%）、髋关节（增长78.6%）、手部（增长48.6%）以及其他关节（如肘关节和肩关节，增长95.1%）的患病率增长率最为显着。这种快速增长凸显了对便捷有效的镇痛技术的迫切需求，也表明疼痛管理设备对于应对骨关节炎的长期影响至关重要。

根据发表在《柳叶刀神经病学》的《2021年全球疾病负担研究》，神经系统疾病影响34亿人，占世界人口的43%，是导致残疾和健康问题的主要原因之一。紧张性头痛（约20亿例）和偏头痛（11亿例）仍然十分普遍。包括靶向枕神经在内的神经刺激系统已被证明能有效阻断疼痛讯号，缓解慢性头痛和偏头痛。同时，糖尿病性神经病变的盛行率自1990年以来增长了两倍多，到2021年达到2.06亿，这推动了旨在缓解神经相关疼痛的设备得到广泛应用。

癌症、骨关节炎和神经系统疾病的日益普遍，加上领先企业不断进行产品创新，为全球疼痛管理设备市场的扩张创造了非常有利的环境。

然而，全球疼痛管理设备市场的成长受到三大主要限制因素的显着阻碍：设备和手术成本高昂、法律规范严格复杂，以及植入式设备固有的风险和併发症。高昂的成本构成高成本障碍，因为神经刺激设备等先进设备的製造成本高昂，相关的手术费用对许多患者和医疗系统而言难以承受，而且报销往往不稳定。此外，法规环境也充满挑战。高风险设备冗长且成本高昂的核准流程扼杀了创新，并延缓了新技术进入市场。最后，患者和医生对手术风险和潜在的设备特异性併发症（例如导线移位和疗效随时间推移而降低）的担忧限制了他们对设备的接受度。儘管对无鸦片类药物疼痛管理解决方案的需求日益增长，但这些因素共同构成了重大障碍，阻碍了市场充分发挥其潜力。

在神经刺激设备领域，脊髓刺激设备（SCS）预计将在 2024 年占据神经刺激设备市场 45% 以上的份额。这一主导地位主要是由于 SCS 作为治疗慢性顽固性疼痛的标准疗法在临床上广泛应用。

神经刺激设备市场正经历显着成长，这主要得益于多种因素的共同作用。慢性疾病（例如慢性疼痛）的全球盛行率不断上升，日益加重的疾病负担推动了对有效、长期治疗方案的需求。此外，技术的重大进步也使这些设备更加有效且易于使用。小型可充电植入、能够即时回应神经活动的「封闭回路型」系统以及经颅磁刺激 (TMS) 等非侵入性疗法的开发，都在推动这些设备的普及应用。此外，更有利的法规环境和更完善的报销政策也使患者更容易获得这些治疗。这包括监管机构广泛核准神经刺激设备的新用途，以及保险公司提供更全面的保险覆盖。

根据世界卫生组织（WHO）（2023 年）的数据，目前约有 6.19 亿人患有腰痛，预计到 2050 年这一数字将达到 8.43 亿人。同时，欧洲疼痛联盟（2023 年）报告称，全球整体约有 7.4 亿人一生中至少会经历一次剧烈疼痛，近 20% 的人患有持续超过三个月的慢性疼痛。

脊髓刺激设备（SCS）作为治疗方法，正日益受到关注。 SCS透过向脊髓刺激设备输送靶向电脉衝，阻断疼痛讯号到达大脑，从而显着改善患者的治疗方法品质。

此外，美国国立卫生研究院 (NIH) 于 2023 年发表的一项研究表明，10% 至 40% 的患者在脊椎手术后会患上腰椎手术失败症候群 (FBSS)。随着椎间盘突出、椎管狭窄和椎间盘退化性疾病等疾病的脊椎手术数量增加，FBSS 的盛行率也持续上升。由于反覆手术风险高且往往无法提供持久的疼痛缓解，脊椎脊髓刺激设备作为一种有效的替代方案正日益受到认可。脊髓刺激器具有降低阿片类药物依赖性、改善功能预后和降低长期医疗保健成本的潜力，使其成为更受欢迎的治疗选择，尤其适用于 FBSS 和慢性神经病变疼痛患者。

2024 年 4 月，美敦力公司获得 FDA核准推出 Inceptiv™，这是首个闭合迴路SCS 系统，它利用即时生物回馈（诱发复合动作电位，ECAP）自动调节刺激，即使在日常活动中也能保持最佳治疗效果。

2023年4月，百多力（Biotronik）的Prospera脊髓刺激系统获得FDA核准。该系统采用RESONANCE技术，这是首个多相刺激模式；同时还配备了Embrace One系统，这是一种以患者为中心的护理模式，可提供自动化、客观的日常远端核准、持续管理和支援。该系统还包括HomeStream远端系统管理、可充电植入，并相容于全身MRI成像。

这些进步都凸显了 SCS 市场的发展轨迹，即从需要定期在诊所进行调整的传统固定输出设备，转向强调远端照护、个人化和工作流程效率的智慧自适应系统。

疼痛管理设备市场区域分析

北美疼痛管理设备市场趋势

在美国的引领下，北美将在2024年占据全球疼痛管理设备市场45%的份额。北美疼痛管理设备市场正经历强劲成长，这主要归功于三个因素：慢性疼痛负担日益加重、近期产品创新和核准激增以及政府支持措施。

根据美国疾病管制与预防中心（CDC）的最新数据，预计到2021年，美国将有5,160万美国（占总人口的20.9%）患有慢性疼痛。其中，有相当一部分人（1,710万人）遭受严重的慢性疼痛，严重影响了他们的日常生活能力。人口老化加剧了这个问题，老年人更容易患上关节炎等慢性疾病。 CDC指出，2022年美国确诊关节炎的年龄调整盛行率将达到18.9%，75岁以上族群的盛行率将飙升至53.9%。慢性疼痛的普遍流行使得人们对超越传统药物的有效长期疼痛管理方案产生了巨大且持续的需求。

市场成长也得益于近期一系列改变治疗方式的产品核准和上市。这些新型设备通常采用微创技术，并融合了人工智慧 (AI) 和闭合迴路系统等先进技术，能够提供更个人化和有效的治疗。例如，Nevro 公司于 2024 年 9 月推出了 HFX AdaptivAI，这是一款由人工智慧驱动的脊髓刺激 (SCS) 系统。同样，雅培公司于 2022 年 12 月获得了 FDA 对其 Eterna™ SCS 系统的核准，这是目前最小的可植入式、可充电的 SCS 系统，用于治疗慢性疼痛。该系统采用专有的低剂量 BurstDR™ 刺激技术，与传统 SCS 相比，疼痛缓解效果提高了 23%。此外，类风湿性关节炎，例如 SetPoint Medical 公司的 SetPoint 系统，这是第一个用于治疗类风湿性关节炎的神经免疫调节设备，于 2025 年 7 月获得 FDA核准，为病情控制不佳的患者提供了药物以外的替代方案。

这些倡议，例如美国将九月定为“疼痛意识月”，旨在教育公众了解早期疗育的重要性以及非阿片类镇痛方法的可用性。这种关注的转变是对鸦片类药物危机的直接回应，美国国立卫生美国(NIH) 和美国食品药物管理局 (FDA) 等机构正在推广更安全的替代疗法。

欧洲疼痛管理医疗设备市场趋势

欧洲疼痛管理医疗设备市场是一个充满活力且不断发展的产业，其发展趋势与北美市场既有相似之处，也有不同之处。

亚太地区疼痛管理设备

该市场是一个高成长地区，其复合年增长率超过了北美和欧洲，而这种快速扩张是由独特的人口和经济趋势所驱动的。

以下列出了疼痛管理设备市场的主要企业，它们总合占据最大的市场份额，并引领着行业趋势：

  • Abbott Laboratories
  • Smith's Medical
  • B. Braun SE
  • Baxter International
  • Boston Scientific Corp.
  • Avanos Medical, Inc.
  • Medtronic
  • Nevro Corp.
  • ICU Medical, Inc.
  • Omron Corporation
  • Stimwave LLC
  • Nipro
  • O&M Halyard
  • EndoStim Inc.
  • Nalu Medical, Inc.
  • Micrel Medical Devices SA
  • DyAnsys, Inc.
  • NanoVibronix, Inc.
  • Zynex Inc.
  • 其他的

疼痛管理设备市场的竞争格局呈现中等集中度，少数几家大型跨国公司主导高价值的神经刺激领域。美敦力、波士顿科学和雅培等公司是主要参与企业，它们凭藉强大的研发能力、可靠的临床证据和完善的全球分销网络，维持着显着的市场份额，尤其是在脊髓刺激设备（SCS）等植入式设备领域。然而，随着Nevro和Saluda Medical等规模较小、更具创新精神的新兴企业不断推出射频和封闭回路型刺激系统等颠覆性技术，这种格局正在改变。这些新参与企业正在推动创新，专注于特定细分市场，并提供更个人化、先进的解决方案，挑战大型企业的统治地位。非侵入性和非处方（OTC）领域则更为分散，OMRON和Zynex等公司凭藉种类繁多的便携式、用户友好型设备展开竞争。这反映出居家照护和远距照护的趋势，正在重塑整个市场的竞争格局。

  • 2025年8月，用于治疗三叉神经痛的NeuroOne OneRF™射频消融系统获得FDA核准。预计2025年秋季上市。
  • 2025年5月，商业化阶段的生物电子技术公司electroCore, Inc.完成了与NeuroMetrix, Inc.的合併，从而确立了其在非侵入式健康和保健解决方案领域多元化领先地位。 NeuroMetrix, Inc.的Quell®纤维肌痛解决方案的加入，扩展了electroCore, Inc.的生物电子疗法产品组合，增强了其在退伍军人事务部（VA）医院系统中的地位，并显着扩大了其在慢性疼痛和健康管理领域的潜在市场。
  • 2025 年 4 月，主要企业Globus Medical, Inc. 宣布完成对 Nevro Corp. 的收购，Nevro Corp. 是一家全球医疗设备创新者，专注于为慢性疼痛管理提供创新解决方案。

疼痛管理设备市场细分

  • 疼痛管理设备（按设备类型划分）
  • 电刺激设备
  • 神经刺激设备
  • 脊髓刺激设备
  • 深层脑部刺激器
  • 荐骨神经刺激器
  • 其他的
  • 经皮电刺激（TENS）
  • 其他的
  • 镇痛输注泵
  • 鞘内输注泵
  • 体外输液泵
  • 消融装置
  • 射频消融装置
  • 冷冻消融装置
  • 其他的
  • 疼痛管理设备应用
  • 肌肉骨骼疼痛
  • 癌症疼痛
  • 神经病变疼痛
  • 其他的
  • 疼痛管理设备的终端用户趋势
  • 医院
  • 专科诊所
  • 復健中心/物理治疗中心
  • 居家医疗
  • 其他的
  • 按地区分類的疼痛管理设备使用情况
  • 北美疼痛管理设备市场
  • 美国疼痛管理设备市场
  • 加拿大疼痛管理设备市场
  • 墨西哥疼痛管理设备市场
  • 欧洲疼痛管理设备市场
  • 英国疼痛管理设备市场
  • 德国疼痛管理设备市场
  • 法国疼痛管理设备市场
  • 义大利疼痛管理设备市场
  • 西班牙疼痛管理设备市场
  • 其他欧洲疼痛管理设备市场
  • 亚太地区疼痛管理设备市场
  • 中国疼痛管理设备市场
  • 日本疼痛管理设备市场
  • 印度疼痛管理设备市场
  • 澳洲疼痛管理设备市场
  • 韩国疼痛管理设备市场
  • 亚太地区其他疼痛管理设备市场
  • 世界其他地区疼痛管理设备市场
  • 南美洲疼痛管理设备市场
  • 中东疼痛管理设备市场
  • 非洲疼痛管理设备市场

利用人工智慧进行影响分析

人工智慧驱动的创新有望彻底改变疼痛管理设备市场，使其从被动应对转变为主动预防、个人化的护理模式。这项转变主要得益于Nevro和美敦力等公司所开发的闭合迴路系统。这些系统利用人工智慧分析即时患者数据，并自动调整神经刺激疗法，实现更有效、更稳定的疼痛缓解。此外，人工智慧透过分析医学影像和穿戴式感测器数据来增强诊断能力，更准确地识别疼痛原因并预测未来疼痛发作，从而实现及时干预。这项技术也推动了智慧穿戴装置的兴起，使得远端患者监测和家庭护理中的个人化治疗成为可能，这一趋势正迅速发展。此外，人工智慧有望透过脸部和身体变异性分析客观量化疼痛，从而解决医疗保健领域的不平等问题，提供比传统主观方法更客观的评估。儘管在检验和资料隐私方面仍存在挑战，但人工智慧的角色不仅仅是一项功能，而是塑造疼痛管理设备未来发展的基础组成部分，使其在慢性疼痛管理方面更加智慧和高效。

目录

第一章 疼痛管理设备市场报告概述

  • 调查范围
  • 市场区隔
  • 市场假设

2. 疼痛管理设备市场执行摘要

  • 市场概览

第三章：疼痛管理设备市场关键因素分析

  • 市场驱动因素
    • 慢性病及相关疾病盛行率不断上升
    • 从鸦片类药物镇痛过渡到其他镇痛方式
    • 技术和创新方面的进步
    • 有利的监管和报销环境
  • 市场限制与挑战
    • 设备和手术高成本
    • 严格而复杂的法规结构
    • 植入医疗器材的风险和併发症
  • 市场机会
    • 「智慧」与非侵入式科技的兴起

第四章 影响分析

  • 人工智慧驱动的创新和应用
  • 美国关税的影响分析

第五章 监理分析

  • 美国
  • 欧洲
  • 日本
  • 中国

第六章 疼痛管理设备市场：波特五力分析

第七章 疼痛管理设备市场评估

  • 依设备类型
    • 电刺激设备
    • 止痛药输注泵
    • 消融装置
    • 其他的
  • 透过使用
    • 肌肉骨骼疼痛
    • 癌症疼痛
    • 神经病变疼痛
  • 最终用户
    • 医院
    • 专科诊所
    • 復健中心/物理治疗中心
    • 居家医疗设备
  • 地区
    • 北美洲
    • 欧洲
    • 亚太地区
    • 其他地区

第八章 竞争情势

第九章Start-Ups资金筹措与投资趋势

10. 疼痛管理设备市场中的公司与产品概况

  • Abbott Laboratories
  • Smith's Medical
  • B. Braun SE
  • Baxter International
  • Boston Scientific Corp.
  • Avanos Medical, Inc.
  • Medtronic
  • Nevro Corp.
  • Abbott
  • ICU Medical, Inc.
  • Omron Corporation
  • Stimwave LLC
  • Nipro
  • O&M Halyard
  • EndoStim Inc.
  • Nalu Medical, Inc.
  • Micrel Medical Devices SA
  • DyAnsys, Inc.
  • NanoVibronix, Inc.
  • Zynex Inc.

第十一章：KOL视角

第十二章计划方法

第十三章：关于 DelveInsight

第十四章 免责声明和联络我们

Product Code: DIMDCL0060

Pain Management Devices Market Summary

  • The global pain management devices market is expected to increase from USD 5,277.30 million in 2024 to USD 9,350.72 million by 2032, reflecting strong and sustained growth.
  • The global pain management devices market is growing at a CAGR of 7.53% during the forecast period from 2025 to 2032.
  • The global pain management devices market is set to grow rapidly from 2025 to 2032, driven by the rising prevalence of chronic pain, frequent product launches, and increasing awareness of pain management solutions. Growing demand for minimally invasive devices and supportive awareness campaigns are boosting adoption, creating strong opportunities for innovation and improved patient outcomes.
  • The leading companies operating in the pain management devices market include Abbott Laboratories, Smith's Medical, B. Braun SE, Baxter International, Boston Scientific Corp., Avanos Medical, Inc., Medtronic, Nevro Corp., ICU Medical, Inc., Omron Corporation, Stimwave LLC, Nipro, O&M Halyard, EndoStim Inc., Nalu Medical, Inc., Micrel Medical Devices SA, DyAnsys, Inc., NanoVibronix, Inc., Zynex Inc., and Others.
  • North America is expected to remain a dominant force in the pain management devices market, driven by the high burden of chronic pain, increasing awareness initiatives, supportive government programs, and continuous product innovations with frequent FDA approvals.
  • In the device type segment of the pain management devices market, the Neurostimulation devices category is estimated to account for the largest market share in 2024.

Factors Contributing to the Growth of the Pain Management Devices Market

  • The Growing Prevalence of Chronic Pain and Related Conditions Leading to a Surge in the Pain Management Devices Market: This is not a single, isolated factor but rather a complex issue stemming from several interconnected demographic and health trends.
  • Aging Population: As life expectancy increases worldwide, the proportion of the population aged 65 and over is growing. This demographic shift is directly linked to a higher prevalence of chronic pain. Older adults are more susceptible to age-related conditions that cause persistent pain, such as:
  • Osteoarthritis: A degenerative joint disease that becomes more common with age.
  • Musculoskeletal disorders: Including back pain, which is one of the leading causes of disability globally.
  • Neuropathic pain: Nerve-related pain that can result from age-related nerve damage.
  • Chronic Diseases: The rising global burden of chronic diseases like diabetes and cancer contributes to a higher prevalence of neuropathic pain and other forms of pain that require long-term management. For instance:
  • Diabetes: Can lead to a type of nerve damage called diabetic neuropathy, which causes chronic pain, tingling, and numbness.
  • Cancer: Both the disease itself and its treatments (e.g., chemotherapy, radiation) can cause severe and persistent pain.
  • Obesity: Places added stress on joints and the skeletal system, leading to a higher incidence of back, knee, and hip pain.
  • Lifestyle Changes: Sedentary lifestyles and occupational factors are leading to a rise in conditions like back pain and other musculoskeletal issues, fueling the demand for non-pharmacological pain relief.
  • Sedentary Lifestyles: Long hours spent sitting at desks or in front of screens can lead to poor posture and chronic back and neck pain.
  • Repetitive Strain Injuries: Certain occupations involve repetitive motions that can lead to conditions like carpal tunnel syndrome or other forms of tendonitis.
  • The Shift Away from Opioid-Based Pain Management: It is a critical factor driving the growth of the pain management devices market, and it is a direct response to a global public health crisis.
  • The Opioid Crisis and Its Impact: The global opioid crisis has highlighted the dangers of addiction, misuse, and abuse associated with traditional pain medications. This has prompted healthcare providers, patients, and regulators to actively seek safer, non-addictive alternatives. Also, the over-prescription of opioid painkillers for both acute and chronic pain led to a public health crisis in many countries, most notably the United States. Key issues include:
  • Addiction and Abuse: Many individuals who were prescribed opioids for pain management developed a dependence or addiction, which can lead to substance use disorder and, in some cases, a transition to more dangerous illicit opioids like heroin or fentanyl.
  • Overdose Deaths: A staggering number of overdose deaths have been attributed to both prescription and illicit opioids, making it a leading cause of unintentional injury deaths.
  • Public and Professional Concern: The scale of the crisis has generated widespread concern among the general public, healthcare providers, and policymakers, leading to a strong push for non-pharmacological alternatives.
  • Reduced Side Effects: Pain management devices, particularly non-invasive ones, offer a way to alleviate pain without the systemic side effects (e.g., drowsiness, nausea, constipation) of oral pain medications.
  • The Rise of Multimodal Pain Management: The shift away from opioids has accelerated the adoption of a multimodal approach to pain management. This involves using a combination of different therapies to achieve optimal pain relief. Pain management devices fit perfectly into this model, as they can be used alongside non-opioid medications (e.g., NSAIDs), physical therapy, and other interventions. For example, a patient recovering from surgery might use a TENS unit to manage their post-operative pain, reducing their need for oral opioids.

In summary, the opioid crisis has acted as a powerful catalyst, forcing a fundamental change in the way pain is treated. This has created a significant market opportunity for pain management devices, which are positioned as a safer, non-addictive, and effective alternative to traditional drug-based pain relief.

  • Technological Advancements and Innovation:
  • Neuromodulation Technologies: Breakthroughs in neurostimulation, such as closed-loop systems and miniaturized implantable devices, are making these treatments more effective, personalized, and less invasive.
  • Smart and Wearable Devices: The development of portable, user-friendly, and wearable devices (like TENS units) allows for convenient, at-home pain management, reducing the need for frequent clinical visits.
  • Integration with Digital Health: The incorporation of artificial intelligence (AI), remote monitoring, and digital health platforms allows for more precise and data-driven pain management, improving patient outcomes.

Pain Management Devices Market Report Segmentation

This pain management devices market report offers a comprehensive overview of the global pain management devices market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Device Type {Electrical Stimulation Devices [Neurostimulation Devices, (Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, and Others), Transcutaneous Electrical Nerve Stimulation (TENS), and Others], Analgesic Infusion Pumps (Intrathecal Infusion Pumps, External Infusion Pumps), Ablation Devices (Radiofrequency Ablation Devices, Cryoablation Devices), and Others}, Application (Musculoskeletal Pain, Cancer Pain, Neuropathic Pain, and Others), End-Users (Hospitals, Specialty Clinics, Rehabilitation Centers/Physiotherapy Centers, Homecare Settings, and Others), and Geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing pain management devices market.

Pain management devices are a category of medical equipment designed to alleviate pain without the need for or as an alternative to oral medications, particularly opioids. They work by either stimulating the body's natural pain-relieving mechanisms or by blocking pain signals from reaching the brain. These devices are used to manage a wide range of chronic and acute pain conditions, including those related to musculoskeletal disorders, neuropathic pain, and post-surgical recovery.

The growing prevalence of chronic pain, coupled with an increasing number of product launches and rising awareness of pain management solutions, is expected to drive significant growth in the global pain management devices market. As patient demand for effective and minimally invasive treatments rises, leading companies are introducing advanced devices that expand treatment options while intensifying market competition and innovation. Moreover, awareness campaigns and patient advocacy are fostering greater acceptance and adoption of these technologies worldwide. Collectively, these factors are creating a favorable environment for market expansion, promising improved patient outcomes and enhanced quality of life for individuals suffering from chronic pain during the forecast period of 2025 to 2032.

What are the latest Pain Management Devices Market Dynamics and Trends?

The global pain management devices market is experiencing robust growth, driven by the rising prevalence of chronic pain conditions across oncology, musculoskeletal, and neurological disorders. A significant contributor is cancer-related pain, particularly neuropathic cancer pain (NCP), which often remains inadequately managed with conventional therapies. With cancer cases surging worldwide, including breast, lung, and prostate cancers, the demand for advanced pain management solutions continues to climb. According to DelveInsight (2024), there were approximately 102,000 incident cases of triple-negative breast cancer (TNBC) in the 7MM in 2023. Global breast cancer incidence, which reached 2.3 million cases in 2022, is projected to escalate to 3.36 million by 2045. This expanding patient pool underscores the critical role of innovative devices in delivering effective pain relief and improving quality of life.

The growing burden of musculoskeletal diseases is another major growth driver. According to the Global Burden of Disease (2023), nearly one billion people are projected to have osteoarthritis by 2050, with steep increases anticipated in the knee (+74.9%), hip (+78.6%), hand (+48.6%), and other joints such as the elbow and shoulder (+95.1%). This sharp rise highlights the urgent need for accessible and effective pain-relieving technologies, positioning pain management devices as indispensable in addressing the long-term impact of osteoarthritis.

Neurological conditions further amplify market demand. The Global Burden of Disease Study 2021, published in The Lancet Neurology, reported that neurological disorders affected 3.4 billion people globally, 43% of the world's population, making them the leading cause of disability and ill health. Among these, tension-type headaches (~2 billion cases) and migraines (~1.1 billion cases) remain highly prevalent. Devices such as neurostimulation systems, including those targeting occipital nerves, have proven effective in interrupting pain signals and providing relief for chronic headaches and migraines. Meanwhile, the diabetic neuropathy population has more than tripled since 1990, reaching 206 million in 2021, fueling further adoption of devices designed to alleviate nerve-related pain.

Collectively, the rising incidence of cancer, osteoarthritis, and neurological conditions, coupled with continuous product innovations by leading players, is creating a highly favorable environment for the expansion of the global pain management devices market.

However, the growth of the global pain management devices market is significantly hampered by three main restraints: the high cost of devices and procedures, a stringent and complex regulatory framework, and the inherent risks and complications of implantable devices. The high cost is a major barrier, as advanced devices like neurostimulators are expensive to produce, and their associated surgical costs are prohibitive for many patients and healthcare systems, often compounded by inconsistent insurance reimbursement. Furthermore, the regulatory environment is challenging; a lengthy and costly approval process for high-risk devices stifles innovation and slows the entry of new technologies into the market. Finally, patient and physician adoption is limited by concerns over surgical risks and the potential for device-specific complications, such as lead migration or a loss of efficacy over time, which may necessitate further, costly surgeries. These combined factors create significant hurdles that restrain the market's full potential despite the rising need for non-opioid pain management solutions.

Pain Management Devices Market Segment Analysis

Pain Management Devices Market by Device Type {Electrical Stimulation Devices [Neurostimulation Devices, (Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, and Others), Transcutaneous Electrical Nerve Stimulation (TENS), and Others], Analgesic Infusion Pumps (Intrathecal Infusion Pumps, External Infusion Pumps), Ablation Devices (Radiofrequency Ablation Devices, Cryoablation Devices), and Others}, Application (Musculoskeletal Pain, Cancer Pain, Neuropathic Pain, and Others), End-Users (Hospitals, Specialty Clinics, Rehabilitation Centers/Physiotherapy Centers, Homecare Settings, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

By Device Type: Neurostimulation Device Category Dominates the Market

Within the neurostimulation devices segment, which leads the overall pain management devices market with a share of about 55%, the spinal cord stimulator (SCS) category accounted for more than 45% of the neurostimulation market in 2024. This dominance is primarily attributed to the widespread clinical adoption of SCS as a standard treatment option for chronic and refractory pain.

The market for neurostimulation devices is experiencing substantial growth, driven by a combination of factors. The rising global prevalence of chronic diseases, such as chronic pain. This increased disease burden has created a greater demand for effective, long-term therapeutic options. Furthermore, significant technological advancements have made these devices more effective and user-friendly. Innovations such as smaller, rechargeable implants, "closed-loop" systems that respond to neural activity in real time, and the development of non-invasive options like Transcranial Magnetic Stimulation (TMS) are expanding their adoption. Additionally, a more favorable regulatory environment and improved reimbursement policies are making these treatments more accessible to patients. This includes regulatory bodies approving a wider range of neurostimulators for new applications and insurers providing better coverage. Finally, the aging global population, which has a higher incidence of age-related neurological disorders and chronic pain, further contributes to the market's strong growth trajectory.

According to the World Health Organization (2023), there were approximately 619 million cases of lower back pain (LBP), a figure expected to climb to 843 million by 2050. In parallel, the European Pain Federation (2023) reported that around 740 million people globally experience at least one episode of severe pain during their lifetime, with nearly 20% developing chronic pain lasting more than three months. This growing burden of chronic pain highlights the urgent need for effective and sustainable pain management solutions.

Spinal cord stimulators (SCS) have gained traction as they provide a minimally invasive, drug-free, and reversible therapy option. By delivering targeted electrical impulses to the spinal cord, these devices block pain signals before they reach the brain, significantly improving patients' quality of life. The rising incidence of chronic pain disorders is, therefore, expected to be a major driver of SCS adoption worldwide.

Furthermore, findings published by the NIH (2023) revealed that Failed Back Surgery Syndrome (FBSS) affects 10-40% of patients following spinal surgeries. With the growing volume of spinal procedures for conditions such as herniated discs, spinal stenosis, and degenerative disc disease, the prevalence of FBSS continues to rise. Since repeated surgeries carry higher risks and often fail to deliver lasting pain relief, spinal cord stimulators are increasingly being recognized as an effective alternative. Their ability to reduce dependency on opioids, improve functional outcomes, and lower long-term healthcare costs makes them a preferred treatment choice, particularly for patients with FBSS and chronic neuropathic pain.

Emerging regulatory approvals are catalyzing market growth by enabling easier access to advanced SCS technologies: In April 2024, Medtronic gained FDA approval for Inceptiv(TM), the first closed-loop SCS system to automatically adjust stimulation using real-time biological feedback (evoked compound action potentials, or ECAPs), maintaining optimal therapy even during daily movement. It is also the only FDA-approved closed-loop system offering full-body 3T MRI access with no restrictions, and is touted as the smallest and thinnest fully implantable SCS device.

In April 2023, Biotronik received FDA approval for its Prospera SCS System, featuring RESONANCE, the first multiphase stimulation paradigm, and Embrace One, a patient-centric care model offering automatic, objective, daily remote monitoring, ongoing management, and support. The system also includes HomeStream remote management, rechargeable implants, and full-body MRI compatibility.

Each of these advancements highlights the trajectory of the SCS market, shifting from traditional, fixed-output devices requiring routine in-clinic adjustments to intelligent, adaptive systems that emphasize remote care, personalization, and workflow efficiency.

Pain Management Devices Market Regional Analysis

North America Pain Management Devices Market Trends

North America, led by the U.S., accounted for a dominant ~45% share of the global pain management devices market in 2024. The North American pain management devices market is experiencing robust growth, driven by a trifecta of factors: the increasing burden of chronic pain, a surge in recent product innovations and approvals, and supportive government initiatives.

A key driver is the alarming prevalence of chronic pain across the region. According to recent data from the Centers for Disease Control and Prevention (CDC), in 2021, an estimated 51.6 million U.S. adults, or 20.9% of the population, were living with chronic pain. A significant subset of this group, 17.1 million individuals, experienced high-impact chronic pain that severely limits daily activities. This is further compounded by the aging demographic, which is more susceptible to chronic conditions like arthritis. The CDC highlights that in 2022, the age-adjusted prevalence of diagnosed arthritis in the U.S. was 18.9%, with a sharp increase to 53.9% in adults aged 75 and older. This widespread prevalence of chronic, debilitating pain creates an immense and sustained demand for effective, long-term pain management solutions beyond traditional pharmaceuticals.

The market's growth is also being fueled by a flurry of recent product approvals and launches that are transforming the treatment landscape. These new devices are often minimally invasive, incorporating advanced technologies like artificial intelligence (AI) and closed-loop systems to offer more personalized and effective therapy. For instance, in September 2024, Nevro launched HFX AdaptivAI, an AI-driven spinal cord stimulation (SCS) system that uses real-time patient feedback to personalize therapy. Similarly, in December 2022, Abbott received FDA approval for its Eterna(TM) SCS system, the smallest implantable, rechargeable SCS available for chronic pain treatment. It uses proprietary low-dose BurstDR(TM) stimulation, which has shown a 23% greater reduction in pain compared to traditional SCS. Furthermore, recent innovations are also targeting specific conditions, such as SetPoint Medical's SetPoint System, which received FDA approval in July 2025 as the first neuroimmune modulation device for rheumatoid arthritis, offering a non-pharmaceutical alternative for patients with inadequately managed disease.

Finally, increasing government initiatives and public awareness campaigns are further propelling market growth. These efforts, such as the designation of September as Pain Awareness Month in the U.S., aim to educate the public on the importance of early intervention and the availability of non-opioid pain relief methods. This shift in focus is a direct response to the opioid crisis, with institutions like the National Institutes of Health (NIH) and the FDA promoting safer alternatives. The robust regulatory framework and favorable reimbursement policies for advanced procedures also incentivize the adoption of these innovative devices, making them more accessible to a wider patient population.

Europe Pain Management Devices Market Trends

The pain management devices market in Europe is a dynamic and growing sector, driven by trends that are both similar to and distinct from those in North America. The market is projected to grow at a significant compound annual growth rate (CAGR) in the coming years, with key drivers and trends shaping its trajectory.

Asia-Pacific Pain Management Devices Market Trends

The Asia-Pacific pain management devices market is a high-growth region, poised to outpace North America and Europe in terms of compound annual growth rate (CAGR). This rapid expansion is driven by a unique set of demographic and economic trends.

Who are the major players in the Pain Management Devices Market?

The following are the leading companies in the pain management devices market. These companies collectively hold the largest market share and dictate industry trends.

  • Abbott Laboratories
  • Smith's Medical
  • B. Braun SE
  • Baxter International
  • Boston Scientific Corp.
  • Avanos Medical, Inc.
  • Medtronic
  • Nevro Corp.
  • ICU Medical, Inc.
  • Omron Corporation
  • Stimwave LLC
  • Nipro
  • O&M Halyard
  • EndoStim Inc.
  • Nalu Medical, Inc.
  • Micrel Medical Devices SA
  • DyAnsys, Inc.
  • NanoVibronix, Inc.
  • Zynex Inc.
  • Others

How is the competitive landscape shaping the pain management devices market?

The competitive landscape of the pain management devices market is defined by a moderate degree of concentration, with a handful of major multinational corporations dominating the high-value, neurostimulation segment. Companies like Medtronic, Boston Scientific, and Abbott Laboratories are the key players, leveraging their extensive R&D capabilities, strong clinical evidence, and established global distribution networks to maintain a significant market share, particularly in implantable devices like spinal cord stimulators (SCS). However, this dynamic is evolving as the market is also populated by a growing number of smaller, innovative players and startups, such as Nevro and Saluda Medical, which are introducing disruptive technologies like high-frequency and closed-loop stimulation systems. These new entrants are driving innovation and challenging the dominance of the larger firms by focusing on specific niches and offering advanced, more personalized solutions. The non-invasive and over-the-counter (OTC) segments are more fragmented, with companies like Omron and Zynex competing with a broad range of portable, user-friendly devices, reflecting a shift towards at-home and remote care that is reshaping competitive strategies across the entire market.

Recent Developmental Activities in the Pain Management Devices Market

  • In August 2025, the FDA cleared NeuroOne OneRF(TM) Radiofrequency Ablation System targeting trigeminal neuralgia via RF ablation, a minimally invasive alternative to traditional interventions. Planned commercial launch in fall 2025.
  • In May 2025, electroCore, Inc., a commercial-stage bioelectronic technology company, completed its merger with NeuroMetrix, Inc., positioning itself as a diversified leader in non-invasive health and wellness solutions. The addition of NeuroMetrix's Quell(R) Fibromyalgia Solution broadens electroCore's portfolio of bioelectronic therapies, enhances its presence within the VA Hospital System, and significantly expands its addressable market in chronic pain and wellness management.
  • In April 2025, Globus Medical, Inc., a leading musculoskeletal technology company, announced the completion of its previously disclosed acquisition of Nevro Corp., a global innovator in medical devices focused on delivering transformative solutions for chronic pain management.

Pain Management Devices Market Segmentation

  • Pain Management Devices by Device Type Exposure
  • Electrical Stimulation Devices
  • Neurostimulation Devices
  • Spinal Cord Stimulators
  • Deep Brain Stimulators
  • Sacral Nerve Stimulators
  • Others
  • Transcutaneous Electrical Nerve Stimulation (TENS)
  • Others
  • Analgesic Infusion Pumps
  • Intrathecal Infusion Pumps
  • External Infusion Pumps
  • Ablation Devices
  • Radiofrequency Ablation Devices
  • Cryoablation Devices
  • Others
  • Pain Management Devices Application Exposure
  • Musculoskeletal Pain
  • Cancer Pain
  • Neuropathic Pain
  • Others
  • Pain Management Devices End-Users Exposure
  • Hospitals
  • Specialty Clinics
  • Rehabilitation Centers / Physiotherapy Centers
  • Homecare Settings
  • Others
  • Pain Management Devices Geography Exposure
  • North America Pain Management Devices Market
  • United States Pain Management Devices Market
  • Canada Pain Management Devices Market
  • Mexico Pain Management Devices Market
  • Europe Pain Management Devices Market
  • United Kingdom Pain Management Devices Market
  • Germany Pain Management Devices Market
  • France Pain Management Devices Market
  • Italy Pain Management Devices Market
  • Spain Pain Management Devices Market
  • Rest of Europe Pain Management Devices Market
  • Asia-Pacific Pain Management Devices Market
  • China Pain Management Devices Market
  • Japan Pain Management Devices Market
  • India Pain Management Devices Market
  • Australia Pain Management Devices Market
  • South Korea Pain Management Devices Market
  • Rest of Asia-Pacific Pain Management Devices Market
  • Rest of the World Pain Management Devices Market
  • South America Pain Management Devices Market
  • Middle East Pain Management Devices Market
  • Africa Pain Management Devices Market

Impact Analysis

AI-Powered Innovations and Applications:

AI-powered innovations are set to revolutionize the pain management devices market by transitioning it from a reactive to a proactive and personalized model of care. This transformation is primarily driven by the development of closed-loop systems, such as those from Nevro and Medtronic, which use AI to analyze real-time patient data and automatically adjust neurostimulation therapy for more effective and consistent pain relief. Furthermore, AI is enhancing diagnostics by analyzing medical images and wearable sensor data to more accurately identify the source of pain and predict future flare-ups, allowing for timely intervention. The technology also supports the rise of smart and wearable devices, enabling remote patient monitoring and personalized therapy in home care settings, a trend that is gaining significant traction. Additionally, AI holds promise in addressing healthcare disparities by objectively quantifying pain through the analysis of facial expressions and body movements, offering a more unbiased assessment than traditional subjective methods. Despite challenges related to validation and data privacy, AI's role is not merely as a feature but as a fundamental component that will shape the future of pain management devices, making them more intelligent and effective in combating chronic pain.

U.S. Tariff Impact Analysis on the Pain Management Devices Market:

The U.S. government's tariffs have had a complex and disruptive impact on the pain management devices market, primarily by raising costs for manufacturers and consumers. Tariffs on imports from key suppliers, notably China and the EU, have forced companies to either absorb costs, thus reducing profit margins, or pass them on to healthcare providers, potentially limiting patient access to care. This has also exposed the fragility of global supply chains, prompting a strategic shift toward diversification, with companies relocating manufacturing to countries with more favorable trade agreements or re-shoring production to the U.S. Furthermore, while tariffs may offer a temporary advantage to some domestic producers, they also create a climate of uncertainty that can deter foreign investment and lead to a re-evaluation of research and development budgets, ultimately impacting the pace of innovation within the market.

How This Analysis Helps Clients

  • Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
  • Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
  • Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
  • Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the pain management devices market report study

  • Market size analysis for the current pain management devices market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the pain management devices market.
  • Various opportunities available for the other competitors in the pain management devices market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current pain management devices market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for the pain management devices market growth in the future?

Frequently Asked Questions for the Pain Management Devices Market

1. What is the growth rate of the pain management devices market?

  • The pain management devices market is estimated to grow at a CAGR of 7.53% during the forecast period from 2025 to 2032.

2. What is the market for pain management devices?

3. The pain management devices market was valued at USD 5,277.30 million in 2024, and is expected to reach USD 9,350.72 million by 2032.

4. Which region has the highest share in the pain management devices market?

  • North America is expected to remain a dominant force in the pain management devices market, driven by the high burden of chronic pain, increasing awareness initiatives, supportive government programs, and continuous product innovations with frequent FDA approvals.

5. What are the drivers for the pain management devices market?

  • The global pain management devices market is set to grow rapidly from 2025 to 2032, driven by the rising prevalence of chronic pain, frequent product launches, and increasing awareness of pain management solutions. Growing demand for minimally invasive devices and supportive awareness campaigns are boosting adoption, creating strong opportunities for innovation and improved patient outcomes.

6. Who are the key players operating in the pain management devices market?

  • Some of the key market players operating in the pain management devices market include Abbott Laboratories, Smith's Medical, B. Braun SE, Baxter International, Boston Scientific Corp., Avanos Medical, Inc., Medtronic, Nevro Corp., Abbott, ICU Medical, Inc., Omron Corporation, Stimwave LLC, Nipro, O&M Halyard, EndoStim Inc., Nalu Medical, Inc., Micrel Medical Devices SA, DyAnsys, Inc., NanoVibronix, Inc., Zynex Inc., and Others.

Table of Contents

1. Pain Management Devices Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumption

2. Pain Management Devices Market Executive Summary

  • 2.1 Market at Glance

3. Pain Management Devices Market Key Factors Analysis

  • 3.1 Pain Management Devices Market Drivers
    • 3.1.1 Rising Prevalence of Chronic and Related Conditions
    • 3.1.2 Shift Away from Opioid-Based Pain Management
    • 3.1.3 Advancements in Technology and Innovation
    • 3.1.4 Favourable Regulatory and Reimbursement Landscape
  • 3.2 Pain Management Devices Market Restraints and Challenges
    • 3.2.1 High Cost of Devices and Procedures
    • 3.2.2 Stringent and Complex Regulatory Frameworks
    • 3.2.3 Risks and Complications of Implantable Devices
  • 3.3 Pain Management Devices Market Opportunity
    • 3.3.1 Rise of "Smart" and Non-Invasive Technologies

4. Impact Analysis

  • 4.1 AI-Powered Innovations and Applications
  • 4.2 U.S. Tariff Impact Analysis

5. Regulatory Analysis

  • 5.1 The United States
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China

6. Pain Management Devices Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Consumers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Pain Management Devices Market Assessment

  • 7.1 By Device Type
    • 7.1.1 Electrical Stimulation Devices
      • 7.1.1.1 Neurostimulation Devices
      • 7.1.1.1.1 Spinal Cord Stimulators
      • 7.1.1.1.2 Deep Brain Stimulators
      • 7.1.1.1.3 Sacral Nerve Stimulators
      • 7.1.1.1.4 Others
      • 7.1.1.2 Transcutaneous Electrical Nerve Stimulation (TENS)
      • 7.1.1.3 Others
    • 7.1.2 Analgesic Infusion Pumps
      • 7.1.2.1 Intrathecal Infusion Pumps
      • 7.1.2.2 External Infusion Pumps
    • 7.1.3 Ablation Devices
      • 7.1.3.1 Radiofrequency Ablation Devices
      • 7.1.3.2 Cryoablation Devices
    • 7.1.4 Others
  • 7.2 By Application
    • 7.2.1 Musculoskeletal Pain
    • 7.2.2 Cancer Pain
    • 7.2.3 Neuropathic Pain
    • 7.2.4 Others
  • 7.3 By End-Users
    • 7.3.1 Hospitals
    • 7.3.2 Specialty Clinics
    • 7.3.3 Rehabilitation Centers / Physiotherapy Centers
    • 7.3.4 Homecare Settings
    • 7.3.5 Others
  • 7.4 By Geography
    • 7.4.1 North America
      • 7.4.1.1 United States Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.1.2 Canada Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.1.3 Mexico Pain Management Devices Market Size in USD million (2022-2032)
    • 7.4.2 Europe
      • 7.4.2.1 France Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.2.2 Germany Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.2.3 United Kingdom Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.2.4 Italy Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.2.5 Spain Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.2.6 Rest of Europe Pain Management Devices Market Size in USD million (2022-2032)
    • 7.4.3 Asia-Pacific
      • 7.4.3.1 China Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.3.2 Japan Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.3.3 India Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.3.4 Australia Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.3.5 South Korea Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.3.6 Rest of Asia-Pacific Pain Management Devices Market Size in USD million (2022-2032)
    • 7.4.4 Rest of the World (RoW)
      • 7.4.4.1 Middle East Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.4.2 Africa Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.4.3 South America Pain Management Devices Market Size In USD Million (2022-2032)

8. Competitive Landscape

9. Startup Funding & Investment Trends

10. Pain Management Devices Market Company and Product Profiles

  • 10.1 Abbott Laboratories
    • 10.1.1 Company Overview
    • 10.1.2 Company Snapshot
    • 10.1.3 Financial Overview
    • 10.1.4 Product Listing
    • 10.1.5 Entropy
  • 10.2 Smith's Medical
    • 10.2.1 Company Overview
    • 10.2.2 Company Snapshot
    • 10.2.3 Financial Overview
    • 10.2.4 Product Listing
    • 10.2.5 Entropy
  • 10.3 B. Braun SE
    • 10.3.1 Company Overview
    • 10.3.2 Company Snapshot
    • 10.3.3 Financial Overview
    • 10.3.4 Product Listing
    • 10.3.5 Entropy
  • 10.4 Baxter International
    • 10.4.1 Company Overview
    • 10.4.2 Company Snapshot
    • 10.4.3 Financial Overview
    • 10.4.4 Product Listing
    • 10.4.5 Entropy
  • 10.5 Boston Scientific Corp.
    • 10.5.1 Company Overview
    • 10.5.2 Company Snapshot
    • 10.5.3 Financial Overview
    • 10.5.4 Product Listing
    • 10.5.5 Entropy
  • 10.6 Avanos Medical, Inc.
    • 10.6.1 Company Overview
    • 10.6.2 Company Snapshot
    • 10.6.3 Financial Overview
    • 10.6.4 Product Listing
    • 10.6.5 Entropy
  • 10.7 Medtronic
    • 10.7.1 Company Overview
    • 10.7.2 Company Snapshot
    • 10.7.3 Financial Overview
    • 10.7.4 Product Listing
    • 10.7.5 Entropy
  • 10.8 Nevro Corp.
    • 10.8.1 Company Overview
    • 10.8.2 Company Snapshot
    • 10.8.3 Financial Overview
    • 10.8.4 Product Listing
    • 10.8.5 Entropy
  • 10.9 Abbott
    • 10.9.1 Company Overview
    • 10.9.2 Company Snapshot
    • 10.9.3 Financial Overview
    • 10.9.4 Product Listing
    • 10.9.5 Entropy
  • 10.10 ICU Medical, Inc.
    • 10.10.1 Company Overview
    • 10.10.2 Company Snapshot
    • 10.10.3 Financial Overview
    • 10.10.4 Product Listing
    • 10.10.5 Entropy
  • 10.11 Omron Corporation
    • 10.11.1 Company Overview
    • 10.11.2 Company Snapshot
    • 10.11.3 Financial Overview
    • 10.11.4 Product Listing
    • 10.11.5 Entropy
  • 10.12 Stimwave LLC
    • 10.12.1 Company Overview
    • 10.12.2 Company Snapshot
    • 10.12.3 Financial Overview
    • 10.12.4 Product Listing
    • 10.12.5 Entropy
  • 10.13 Nipro
    • 10.13.1 Company Overview
    • 10.13.2 Company Snapshot
    • 10.13.3 Financial Overview
    • 10.13.4 Product Listing
    • 10.13.5 Entropy
  • 10.14 O&M Halyard
    • 10.14.1 Company Overview
    • 10.14.2 Company Snapshot
    • 10.14.3 Financial Overview
    • 10.14.4 Product Listing
    • 10.14.5 Entropy
  • 10.15 EndoStim Inc.
    • 10.15.1 Company Overview
    • 10.15.2 Company Snapshot
    • 10.15.3 Financial Overview
    • 10.15.4 Product Listing
    • 10.15.5 Entropy
  • 10.16 Nalu Medical, Inc.
    • 10.16.1 Company Overview
    • 10.16.2 Company Snapshot
    • 10.16.3 Financial Overview
    • 10.16.4 Product Listing
    • 10.16.5 Entropy
  • 10.17 Micrel Medical Devices SA
    • 10.17.1 Company Overview
    • 10.17.2 Company Snapshot
    • 10.17.3 Financial Overview
    • 10.17.4 Product Listing
    • 10.17.5 Entropy
  • 10.18 DyAnsys, Inc.
    • 10.18.1 Company Overview
    • 10.18.2 Company Snapshot
    • 10.18.3 Financial Overview
    • 10.18.4 Product Listing
    • 10.18.5 Entropy
  • 10.19 NanoVibronix, Inc.
    • 10.19.1 Company Overview
    • 10.19.2 Company Snapshot
    • 10.19.3 Financial Overview
    • 10.19.4 Product Listing
    • 10.19.5 Entropy
  • 10.20 Zynex Inc.
    • 10.20.1 Company Overview
    • 10.20.2 Company Snapshot
    • 10.20.3 Financial Overview
    • 10.20.4 Product Listing
    • 10.20.5 Entropy

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer & Contact Us

List of Tables

  • Table 1: Pain Management Devices Market in Global (2022-2032)
  • Table 2: Pain Management Devices Market in Global by Device Type (2022-2032)
  • Table 3: Pain Management Devices Market in Global by Application (2022-2032)
  • Table 4: Pain Management Devices Market in Global by End-Users (2022-2032)
  • Table 5: Pain Management Devices Market in Global by Geography (2022-2032)
  • Table 6: Pain Management Devices Market in North America (2022-2032)
  • Table 7: Pain Management Devices Market in the United States (2022-2032)
  • Table 8: Pain Management Devices Market in Canada (2022-2032)
  • Table 9: Pain Management Devices Market in Mexico (2022-2032)
  • Table 10: Pain Management Devices Market in Europe (2022-2032)
  • Table 11: Pain Management Devices Market in France (2022-2032)
  • Table 12: Pain Management Devices Market in Germany (2022-2032)
  • Table 13: Pain Management Devices Market in United Kingdom (2022-2032)
  • Table 14: Pain Management Devices Market in Italy (2022-2032)
  • Table 15: Pain Management Devices Market in Spain (2022-2032)
  • Table 16: Pain Management Devices Market in the Rest of Europe (2022-2032)
  • Table 17: Pain Management Devices Market in Asia-Pacific (2022-2032)
  • Table 18: Pain Management Devices Market in China (2022-2032)
  • Table 19: Pain Management Devices Market in Japan (2022-2032)
  • Table 20: Pain Management Devices Market in India (2022-2032)
  • Table 21: Pain Management Devices Market in Australia (2022-2032)
  • Table 22: Pain Management Devices Market in South Korea (2022-2032)
  • Table 23: Pain Management Devices Market in Rest of Asia-Pacific (2022-2032)
  • Table 24: Pain Management Devices Market in the Rest of the World (2022-2032)
  • Table 25: Pain Management Devices Market in the Middle East (2022-2032)
  • Table 26: Pain Management Devices Market in Africa (2022-2032)
  • Table 27: Pain Management Devices Market in South America (2022-2032)
  • Table 28: Competitive Landscape
  • Table 29: Startup Funding & Investment Trends

List of Figures

  • Table 1: Pain Management Devices Market Drivers
  • Table 2: Pain Management Devices Market Restraints
  • Table 3: Pain Management Devices Market Opportunities
  • Table 4: AI-Powered Innovations in Pain Management Devices Market
  • Table 5: US Tariff Impact on Pain Management Devices Market
  • Table 6: Regulatory Analysis (US, EU, Japan, China)
  • Table 7: Porter's Five Forces Analysis
  • Table 8: Competitive Analysis
  • Table 9: Pain Management Devices Market in Global (2022-2032)
  • Table 10: Pain Management Devices Market in Global by Device Type (2022-2032)
  • Table 11: Pain Management Devices Market in Global by Application (2022-2032)
  • Table 12: Pain Management Devices Market in Global by End-Users (2022-2032)
  • Table 13: Pain Management Devices Market in Global by Geography (2022-2032)
  • Table 14: Pain Management Devices Market in North America (2022-2032)
  • Table 15: Pain Management Devices Market in the United States (2022-2032)
  • Table 16: Pain Management Devices Market in Canada (2022-2032)
  • Table 17: Pain Management Devices Market in Mexico (2022-2032)
  • Table 18: Pain Management Devices Market in Europe (2022-2032)
  • Table 19: Pain Management Devices Market in France (2022-2032)
  • Table 20: Pain Management Devices Market in Germany (2022-2032)
  • Table 21: Pain Management Devices Market in United Kingdom (2022-2032)
  • Table 22: Pain Management Devices Market in Italy (2022-2032)
  • Table 23: Pain Management Devices Market in Spain (2022-2032)
  • Table 24: Pain Management Devices Market in the Rest of Europe (2022-2032)
  • Table 25: Pain Management Devices Market in Asia-Pacific (2022-2032)
  • Table 26: Pain Management Devices Market in China (2022-2032)
  • Table 27: Pain Management Devices Market in Japan (2022-2032)
  • Table 28: Pain Management Devices Market in India (2022-2032)
  • Table 29: Pain Management Devices Market in Australia (2022-2032)
  • Table 30: Pain Management Devices Market in South Korea (2022-2032)
  • Table 31: Pain Management Devices Market in Rest of Asia-Pacific (2022-2032)
  • Table 32: Pain Management Devices Market in the Rest of the World (2022-2032)
  • Table 33: Pain Management Devices Market in the Middle East (2022-2032)
  • Table 34: Pain Management Devices Market in Africa (2022-2032)
  • Table 35: Pain Management Devices Market in South America (2022-2032)
  • Table 36: Competitive Landscape
  • Table 37: Startup Funding & Investment Trends